{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:15:26Z","timestamp":1773814526817,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Cognitive impairment may be associated with aquaporin-4 antibody positive (AQP4+) NMOSD, particularly where there is prominent cerebral, corpus callosum, or thalamic involvement. It is unclear to what extent this phenomenon may be treatable after months to years. We describe two cases of AQP4+ NMOSD with cognitive impairment persisting over more than 6 months, where cognition improved after eculizumab was initiated. In the first case, a 51-year-old woman presented with a 2-month history of cognitive decline and ataxia, and diffuse involvement of the corpus callosum on MRI. AQP4 antibody testing returned positive. Cognitive impairment persisted on therapy with mycophenolate, then rituximab. She was switched to eculizumab from rituximab 18 months after disease onset because of breakthrough optic neuritis; memory and cognitive function improved on eculizumab. In the second case, a 26-year-old woman initially presented with visual, auditory and tactile hallucinations, and impairment in activities of daily living, and was given a diagnosis of schizophrenia. Nine months later she was hospitalized for increasing confusion. MRI showed leukoencephalopathy and diffuse involvement of the corpus callosum with multiple enhancing callosal lesions. AQP4 antibody testing was positive and CSF testing for other antibodies of autoimmune encephalitis was negative. She had some improvement in cognition with high dose corticosteroids but remained significantly impaired. On follow-up, her repeat MRI showed a small new right inferomedial frontal enhancing lesion although she did not complain of any new cognitive issues, her MOCA score was 21\/30, and she was started on eculizumab. Two months after eculizumab initiation she and her family reported cognitive improvement and MOCA score was 25\/30. Common features of these two cases included extensive callosal involvement and an element of ongoing gadolinium enhancement on MRI. Our experience suggests the possibility that cognitive impairment may be amenable to immunotherapy in certain cases of NMOSD.<\/jats:p>","DOI":"10.3389\/fneur.2022.863151","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T08:58:41Z","timestamp":1652432321000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Chronic Cognitive Impairment in AQP4+ NMOSD With Improvement in Cognition on Eculizumab: A Report of Two Cases"],"prefix":"10.3389","volume":"13","author":[{"given":"Georges","family":"Saab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia L.","family":"Rotstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/ana.23721","article-title":"Cognitive impairment and cortical degeneration in neuromyelitis optica","volume":"73","author":"Saji","year":"2013","journal-title":"Ann Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1177\/1352458516636246","article-title":"Cognitive impairment differs between neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"22","author":"Kim","year":"2016","journal-title":"Mult Scler."},{"key":"B3","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3389\/fneur.2019.00608","article-title":"Cognitive impairment in neuromyelitis optica spectrum disorders: a review of clinical and neuroradiological features","volume":"10","author":"Oertel","year":"2019","journal-title":"Front Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1177\/1352458511404917","article-title":"Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder","volume":"17","author":"Kim","year":"2011","journal-title":"Mult Scler"},{"key":"B5","doi-asserted-by":"publisher","first-page":"577693","DOI":"10.1016\/j.jneuroim.2021.577693","article-title":"Psychiatric symptoms as initial manifestation in neuromyelitis optica spectrum disorder without cortical lesions: a report of two cases","volume":"359","author":"Tang","year":"2021","journal-title":"J Neuroimmunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"274.e271","DOI":"10.1016\/j.genhosppsych.2015.02.007","article-title":"Neuromyelitis optica presenting with psychiatric symptoms and catatonia: a case report","volume":"37","author":"Alam","year":"2015","journal-title":"Gen Hosp Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jnnp-2021-327206","article-title":"Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders","volume":"93","author":"Camera","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","first-page":"102153","DOI":"10.1016\/j.msard.2020.102153","article-title":"Overlapping demyelinating syndrome (Neuromyelitis optica spectrum disorders NMOSD with anti-NMDA receptor encephalitis); A case report","volume":"42","author":"Sinani","year":"2020","journal-title":"Multiple Sclerosis Relat Disord"},{"key":"B9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.msard.2019.07.008","article-title":"AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: a case report and literature review","volume":"35","author":"Tao","year":"2019","journal-title":"Multiple Sclerosis Relat Disord"},{"key":"B10","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/1352458512454772","article-title":"Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica","volume":"19","author":"Makino","year":"2013","journal-title":"Mult Scler."},{"key":"B11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.msard.2017.11.004","article-title":"Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: a cohort of Latin American patients","volume":"19","author":"Carnero Contentti","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"722237","DOI":"10.3389\/fneur.2021.722237","article-title":"MRI patterns distinguish AQP4 antibody positive neuromyelitis optica spectrum disorder from multiple sclerosis","volume":"12","author":"Clarke","year":"2021","journal-title":"Front Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1177\/1352458509103301","article-title":"Occurrence of acute large and edematous callosal lesions in neuromyelitis optica","volume":"15","author":"Nakamura","year":"2009","journal-title":"Mult Scler."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1177\/1352458514560928","article-title":"Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: results of a 17-year longitudinal study","volume":"21","author":"Granberg","year":"2015","journal-title":"Mult Scler."},{"key":"B15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/archneur.55.2.193","article-title":"Corpus callosum atrophy is a possible indicator of region- and cell type-specific neuronal degeneration in Alzheimer disease: a magnetic resonance imaging analysis","volume":"55","author":"Hamphel","year":"1998","journal-title":"Arch Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jns.2015.11.031","article-title":"Cognitive and psychiatric comorbidities in neuromyelitis optica","volume":"360","author":"Moore","year":"2016","journal-title":"J Neurol Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s00415-016-8345-3","article-title":"Cognitive dysfunction in adult patients with neuromyelitis optica: a systematic review and metaanalysis","volume":"264","author":"Meng","year":"2017","journal-title":"J Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1212\/WNL.0000000000002067","article-title":"Structural MRI substrates of cognitive impairment in neuromyelitis optica","volume":"85","author":"Liu","year":"2015","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.bandc.2011.05.007","article-title":"Cognitive impairment and whole brain diffusion in patients with neuromyelitis optica after acute relapse","volume":"77","author":"He","year":"2011","journal-title":"Brain Cogn."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e33878","DOI":"10.1371\/journal.pone.0033878","article-title":"White matter atrophy and cognitive dysfunctions in neuromyelitis optica","volume":"7","author":"Blanc","year":"2012","journal-title":"PLoS ONE."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3174\/ajnr.A4403","article-title":"Gray matter volume reduction is associated with cognitive impairment in neuromyelitis optica","volume":"36","author":"Wang","year":"2015","journal-title":"Am J Neuroradiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1093\/brain\/awab102","article-title":"Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders","volume":"144","author":"Takai","year":"2021","journal-title":"Brain"},{"key":"B24","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ana.26067","article-title":"Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker","volume":"89","author":"Aktas","year":"2021","journal-title":"Ann Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.863151\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T08:58:43Z","timestamp":1652432323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.863151\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":24,"alternative-id":["10.3389\/fneur.2022.863151"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.863151","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"article-number":"863151"}}